ASK Capital Investment Managers LLC Purchases 7,058 Shares of Amgen Inc. $AMGN

ASK Capital Investment Managers LLC acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the third quarter, HoldingsChannel reports. The fund acquired 7,058 shares of the medical research company’s stock, valued at approximately $2,975,000. Amgen accounts for 3.3% of ASK Capital Investment Managers LLC’s holdings, making the stock its 15th biggest holding.

A number of other hedge funds have also added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in shares of Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after purchasing an additional 2,261,544 shares during the period. State Street Corp boosted its stake in shares of Amgen by 38.2% during the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Amgen by 12.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company’s stock valued at $1,952,156,000 after purchasing an additional 605,928 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Amgen during the 2nd quarter valued at about $1,831,903,000. Finally, Invesco Ltd. increased its position in shares of Amgen by 7.2% during the fourth quarter. Invesco Ltd. now owns 4,788,460 shares of the medical research company’s stock valued at $1,567,311,000 after buying an additional 321,173 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,642,098.28. This trade represents a 23.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the sale, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock worth $2,540,926 in the last 90 days. Company insiders own 0.85% of the company’s stock.

Amgen Trading Down 1.1%

Shares of NASDAQ:AMGN opened at $412.84 on Wednesday. The company has a market cap of $223.19 billion, a P/E ratio of 25.66, a PEG ratio of 3.01 and a beta of 0.41. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 1 year low of $288.00 and a 1 year high of $447.03. The stock’s fifty day moving average price is $414.16 and its 200-day moving average price is $373.24.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The company had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same period last year, the firm posted $6.02 earnings per share. Amgen’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts expect that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were paid a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.4%. Amgen’s dividend payout ratio is currently 62.65%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Mizuho increased their price target on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 18th. Scotiabank raised their price objective on shares of Amgen from $450.00 to $500.00 and gave the stock an “outperform” rating in a report on Monday, September 28th. Weiss Ratings raised Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. Citigroup lifted their price objective on Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Finally, Guggenheim decreased their target price on Amgen from $388.00 to $378.00 and set a “neutral” rating for the company in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $387.93.

Amgen Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.